Research project
ESCAPE trial
The Exacerbation and Symptom Control after Pseudomonas Eradication (ESCAPE) trial will investigate whether prolonged antibiotics can prevent permanent Pseudomonas infection in bronchiectasis
Active
June 2025
May 2030
Bronchiectasis (BE) is the third most common lung condition in the UK; it causes people to suffer from cough and chest infections. 1 in 3 Bronchiectasis patients develop a further bacterial infection called Pseudomonas, which is difficult to treat as it often becomes resistant to antibiotic tablets.
The Pseudomonas infection worsens the symptoms of Bronchiectasis. The aim of ESCAPE is to establish research backed basis for the best treatment path for new Pseudomonas infections by comparing two currently recommended treatments.
The trial is being funded by the National Institute for Health Research and led by Professor James Chalmers at the University of Dundee. The trial is being managed by Tayside Clinical Trials Unit.
